4 610

Cited 10 times in

Treatment outcome of radiation therapy and concurrent targeted molecular therapy in spinal metastasis from renal cell carcinoma

DC Field Value Language
dc.contributor.author금웅섭-
dc.contributor.author이우중-
dc.contributor.author이정심-
dc.contributor.author조연아-
dc.date.accessioned2017-10-26T07:14:42Z-
dc.date.available2017-10-26T07:14:42Z-
dc.date.issued2016-
dc.identifier.issn2234-1900-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/151790-
dc.description.abstractPURPOSE: To evaluate the clinical outcomes of patients who underwent radiation therapy with or without targeted molecular therapy for the treatment of spinal metastasis from renal cell carcinoma (RCC). MATERIALS AND METHODS: A total of 28 spinal metastatic lesions from RCC patients treated with radiotherapy between June 2009 and June 2015 were retrospectively reviewed. Thirteen lesions were treated concurrently with targeted molecular therapy (concurrent group) and 15 lesions were not (nonconcurrent group). Local control was defined as lack of radiographically evident local progression and neurological deterioration. RESULTS: At a median follow-up of 11 months (range, 2 to 58 months), the 1-year local progression-free rate (LPFR) was 67.0%. The patients with concurrent targeted molecular therapy showed significantly higher LPFR than those without (p = 0.019). After multivariate analysis, use of concurrent targeted molecular therapy showed a tendency towards improved LPFR (hazard ratio, 0.13; 95% confidence interval, 0.01 to 1.16). There was no difference in the incidence of systemic progression between concurrent and nonconcurrent groups. No grade ≥2 toxicities were observed during or after radiotherapy. CONCLUSION: Our study suggests the possibility that concurrent use of targeted molecular therapy during radiotherapy may improve LPFR. Further study with a large population is required to confirm these results.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherKorean Society for Therapeutic Radiology and Oncology-
dc.relation.isPartOfRADIATION ONCOLOGY JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleTreatment outcome of radiation therapy and concurrent targeted molecular therapy in spinal metastasis from renal cell carcinoma-
dc.typeArticle-
dc.publisher.locationKorea (South)-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Radiation Oncology-
dc.contributor.googleauthorSangjoon Park-
dc.contributor.googleauthorKyung Hwan Kim-
dc.contributor.googleauthorWoo Joong Rhee-
dc.contributor.googleauthorJeongshim Lee-
dc.contributor.googleauthorYeona Cho-
dc.contributor.googleauthorWoong Sub Koom-
dc.identifier.doi10.3857/roj.2016.01718-
dc.contributor.localIdA05006-
dc.contributor.localIdA03112-
dc.contributor.localIdA04680-
dc.contributor.localIdA00273-
dc.relation.journalcodeJ02592-
dc.identifier.eissn2234-3164-
dc.relation.journalsince2011~-
dc.identifier.pmid27306772-
dc.relation.journalbefore~2011 Journal of the Korean Society for Therapeutic Radiology and Oncology (대한방사선종양학회지)-
dc.subject.keywordMolecular targeted therapy-
dc.subject.keywordNeoplasm metastasis-
dc.subject.keywordRadiotherapy-
dc.subject.keywordRenal cell carcinoma-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.alternativeNameRhee, Woo Joong-
dc.contributor.alternativeNameLee, Jeong Shim-
dc.contributor.alternativeNameCho, Yeona-
dc.contributor.affiliatedAuthorRhee, Woo Joong-
dc.contributor.affiliatedAuthorLee, Jeong Shim-
dc.contributor.affiliatedAuthorCho, Yeona-
dc.contributor.affiliatedAuthorKoom, Woong Sub-
dc.citation.volume34-
dc.citation.number2-
dc.citation.startPage128-
dc.citation.endPage134-
dc.identifier.bibliographicCitationRADIATION ONCOLOGY JOURNAL, Vol.34(2) : 128-134, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid45801-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.